9H93
Poliovirus type 2 (strain MEF-1) stabilised virus-like particle (PV2 SC6b) from a yeast expression system.
Summary for 9H93
| Entry DOI | 10.2210/pdb9h93/pdb |
| EMDB information | 51951 |
| Descriptor | Capsid protein VP1, Capsid protein, VP0, Capsid protein VP3, ... (4 entities in total) |
| Functional Keywords | capsid protein, virus-like particle, vaccine, virus like particle |
| Biological source | Poliovirus 2 More |
| Total number of polymer chains | 3 |
| Total formula weight | 97260.88 |
| Authors | Bahar, M.W.,Sherry, L.,Stonehouse, N.J.,Rowlands, D.J.,Fry, E.E.,Stuart, D.I. (deposition date: 2024-10-29, release date: 2025-04-02, Last modification date: 2025-04-09) |
| Primary citation | Sherry, L.,Grehan, K.,Bahar, M.W.,Swanson, J.J.,Fox, H.,Matthews, S.,Carlyle, S.,Qin, L.,Porta, C.,Wilkinson, S.,Robb, S.,Clark, N.,Liddell, J.,Fry, E.E.,Stuart, D.I.,Macadam, A.J.,Rowlands, D.J.,Stonehouse, N.J. Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation. Npj Vaccines, 10:64-64, 2025 Cited by PubMed Abstract: The success of the poliovirus (PV) vaccines has enabled the near-eradication of wild PV, however, their continued use post-eradication poses concerns, due to the potential for virus escape during vaccine manufacture. Recombinant virus-like particles (VLPs) that lack the viral genome remove this risk. Here, we demonstrate the production of PV VLPs for all three serotypes by controlled fermentation using Pichia pastoris. We determined the cryo-EM structure of a new PV2 mutant, termed SC5a, in comparison to PV2-SC6b VLPs described previously and investigated the immunogenicity of PV2-SC5a VLPs. Finally, a trivalent immunogenicity trial using bioreactor-derived VLPs of all three serotypes in the presence of Alhydrogel adjuvant, showed that these VLPs outperform the current IPV vaccine in the standard vaccine potency assay, offering the potential for dose-sparing. Overall, these results provide further evidence that yeast-produced VLPs have the potential to be a next-generation polio vaccine in a post-eradication world. PubMed: 40164627DOI: 10.1038/s41541-025-01111-2 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (2.4 Å) |
Structure validation
Download full validation report
